Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 10/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 8/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 8/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ar-42 SCHEMBL31140841 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| Ar-42 SCHEMBL2348844 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL676825 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL3816907 | 0.87 | HDAC1 (0.76) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL2018982 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL14933783 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL675363 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL12681975 | 0.85 | HDAC1 (0.72) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL10343708 | 0.85 | HDAC1 (0.72) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL28317430 | 0.84 | HDAC1 (0.72) | HDAC1HDAC3HDAC8HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-11357748-B2 | Methods for treating mendelian disorders of the epigenetic machinery | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | claimed |
| US-11142508-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-10-12 | — | — | US | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| US-10568854-B2 | Compositions and methods for treating kabuki syndrome and related disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| US-20170100354-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-13 | — | — | US | claimed |
| US-20170095436-A1 | METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-06 | — | — | US | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| WO-2016069854-A1 | ENHANCING THE ANTI-TUMOR, ANTI-VIRAL, AND ANTI-PROTOZOAN EFFECTS OF 2-AMINO-N-[4-[5-PHENANTHREN-2-YL-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL] PHENYL]ACETAMIDE (OSU-03012) AND OTHER PHARMACEUTICAL DRUGS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-05-06 | — | — | WO | claimed |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | BAIOCCHI ROBERT A (US) | 2011-11-17 | — | — | US | claimed |
| WO-2011006040-A2 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES | STOWERS INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-01-13 | — | — | WO | claimed |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-28 | — | — | US | claimed |
| EP-2040731-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | Merrion Research III Limited (IE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007146234-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | MERRION RESEARCH II LIMITED (IE) | 2007-12-21 | — | — | WO | claimed |
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | MERRION RESEARCH II LIMITED (IE) | 2007-12-20 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| US-20070148228-A1 | Solid oral dosage form containing an enhancer | MERRION RESEARCH I LIMITED (IE) | 2007-06-28 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | CEL, SLC10A2, FABP2 | HDAC1 47/4885HDAC3 101/4885HDAC8 113/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC1 1/4885HDAC3 6/4885HDAC8 14/4885 |
| US-11142508-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | AR, SHBG, NR5A1 | HDAC1 181/4885HDAC3 235/4885HDAC8 394/4885 |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | HDAC1, HDAC9, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC8 9/4885 |
| US-20070148228-A1 | Solid oral dosage form containing an enhancer | HDAC5, HDAC4, HDAC7 | HDAC1 7/4885HDAC3 5/4885HDAC8 8/4885 |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC3 8/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.